🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
- This event has passed.
Learn About Our Upcoming Special Access Program (SAP) Workshop
July 20 @ 6:00 pm - 7:00 pm
The SAP is a Health Canada program that allows individuals to receive psilocybin and MDMA assisted therapy when they have exhausted their search for relief for end-of-life distress, Major Depressive Disorders (MDD) and Post-Traumatic Stress Disorder (PTSD) without success.
A prescribing healthcare professional is needed to lead the application, with assistance from therapists or practitioners to carry out the treatment and therapy.
Few Canadian healthcare professionals are familiar with the program and application process. At first glance, most practitioners deem it a challenge to learn and use the SAP.
We hope to change that, as we know there are many compassionate Canadian practitioners who have clients and patients that are desperately seeking a mental wellness solution.
Join us for a live info session with Q&A to discuss how our workshop can help practitioners provide clients and patients access to psychedelic-assisted therapy through the SAP.
What we will discuss:
- Overview of the SAP
- How non-prescribing practitioners can get involved
- SAP application and approvals
- Conducting psychedelic assisted therapy under the SAP
- ATMA’s SAP workshop